Jan Burger, M.D., Ph.D., and Susan O'Brien, M.D., of Leukemia at MD Anderson Cancer Center explain the impact of the targeted therapy drug ibrutinib verses chemotherapy treatment for CLL (chronic lymphocytic leukemia) using laymen's terms.